Get the Stockscreener App
10.61
1.12%
-0.12
Pre-market:
10.65
0.04
+0.38%
Theravance Biopharma Inc stock is traded at $10.61, with a volume of 272.17K.
It is down -1.12% in the last 24 hours and up +18.15% over the past month.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
See More
Previous Close:
$10.73
Open:
$10.78
24h Volume:
272.17K
Relative Volume:
1.00
Market Cap:
$550.51M
Revenue:
$62.02M
Net Income/Loss:
$-45.65M
P/E Ratio:
-11.53
EPS:
-0.92
Net Cash Flow:
$-9.60M
1W Performance:
-3.63%
1M Performance:
+18.15%
6M Performance:
+5.68%
1Y Performance:
+20.29%
1-Day Range:
$10.52
$10.78
1-Week Range:
$10.52
$11.50
52-Week Range:
$7.44
$11.82
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
10.61 | 550.51M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,534 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance and Mylan settle patent dispute with Eugia Pharma - MSN
theravance biopharma settles patent litigation with eugia pharma By Investing.com - Investing.com South Africa
Theravance and Viatris settle patent dispute with Eugia Pharma - Seeking Alpha
Theravance BiopharmaTheravance And Mylan Enter Settlement Agreement With EugiaSEC Filing - marketscreener.com
Theravance Biopharma Settles Patent Litigation with Eugia - TipRanks
theravance biopharma settles patent litigation with eugia pharma - Investing.com
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma Sells Remaining Trelegy Royalties to GSK for $225 Million - Global Legal Chronicle
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises - sharewise
ProShare Advisors LLC Takes Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Bought by Millennium Management LLC - Defense World
BTIG maintains buy rating on Theravance Biopharma stock By Investing.com - Investing.com Canada
Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - marketscreener.com
Theravance Biopharma Sells Trelegy Royalty Interest to GSK - TipRanks
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in T - GuruFocus
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - Eagle-Tribune
Ameriprise Financial Inc. Cuts Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Nuveen Asset Management LLC Buys 48,635 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Deutsche Bank AG Purchases 15,608 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Jane Street Group LLC Has $493,000 Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Bank of America Corp DE Increases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders - Barchart.com
(TBPH) On The My Stocks Page - news.stocktradersdaily.com
Northern Trust Corp Has $3.67 Million Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable - Yahoo Finance
Theravance Biopharma at H.C. Wainwright: Strategic Focus on YUPELRI and Ampreloxetine - Investing.com Canada
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by StockNews.com - Defense World
When (TBPH) Moves Investors should Listen - news.stocktradersdaily.com
Theravance Biopharma to Participate in an Upcoming Investor Conf - GuruFocus
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizen Tribune
Price T Rowe Associates Inc. MD Buys 9,315 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Dimensional Fund Advisors LP Acquires 95,304 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
We Think Some Shareholders May Hesitate To Increase Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation - simplywall.st
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Earnings Call Transcript - Insider Monkey
Theravance Biopharma Announces Ampreloxetine Presentations at th - GuruFocus
Theravance Biopharma, Inc. Announces Ampreloxetine Presentations At the International MSA Congress - marketscreener.com
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y - TradingView
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress | TBPH Stock News - GuruFocus
Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - Stock Titan
Theravance Biopharma: Promising Future with Strong Product Pipeline and Market Expansion - TipRanks
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights - GuruFocus
Tower Research Capital LLC TRC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - The AM Reporter
Wells Fargo & Company MN Has $204,000 Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Theravance Biopharma Inc (TBPH) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Progress Amid Challenges - GuruFocus
Theravance Biopharma Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Theravance Biopharma misses Q1 2025 EPS forecast - Investing.com
Theravance Biopharma Q1 2025 slides: revenue growth amid widening losses - Investing.com Canada
Theravance Biopharma earnings missed by $0.05, revenue topped estimates - Investing.com Canada
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.92%
7.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):